|
PROFILE
Advanced Medical Isotope Corporation is a company engaged in the production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic application. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until recently, have not been feasible or economical, in an effort to detect and cure human disease.
Advanced Medical Isotope Corporation (AMIC) is on the verge of becoming the leading US company in the fast-growing field of Nuclear Medicine, in both diagnostics and therapeutics.
AMIC is engaging in the production and distribution of medical isotopes, such as Molybdenum-99 (Mo-99), as well as medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic applications.
What are Medical Isotopes?
A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease. New technologies enable therapeutic isotopes to be delivered directly to the site of diseased cells. This is different from external beam radiation treatment where radiation is directed from outside the body.
What is Molybdenum-99 (Mo-99)?
Mo-99 is the most commonly used medical isotope in the world and is facing a critical shortage due to a small number of processing facilities and aging reactors. In response to this ongoing crisis, AMIC is developing methods to produce Mo-99 and other radioisotopes without needing a nuclear reactor, instead using a device the approximate size of a commercial cyclotron for production. AMIC has development programs in place to produce Mo-99 with high yields at a significant reduction in cost compared to isotopes made from nuclear plant methods.
AMIC Management
AMIC’s management team includes prominent industry scientists and highly experienced members in business management, medical technology startup firms, and the nuclear technology industry. The senior management team averages over 30 years experience in the nuclear and technology industries, each with extensive experience performing the specific roles assigned within AMIC.
Investment Highlights
- The global market for Oxygen-18 (O-18), a rare and stable isotope target for making the PET isotope Flourine-18 (F-18), is approx. $38M and has been growing almost 20% annually. The market for PET-specific isotopes is currently over $1B, growing over 25% annually, providing a great opportunity for AMIC to position itself as a major supplier of O-18 to other major F-18 FDG manufacturers.
- Technology advances in medical isotope manufacturing allow AMIC to site, build and operate the LINAC isotope production centers at significantly lower costs than traditional cyclotron accelerators, affording AMIC substantial cost reductions and enables AMIC to generate a broader product line.
- AMIC purchased the first Linear Accelerator (LINAC) located in North America specifically designed for the purpose of PET isotopes production, with expanded capability to produce other high demand isotopes.
- AMIC completed the standard PET facility design, the LINAC production facility and the dispensing laboratory, and delivers F-18 FDG to regional customers.
- AMIC is currently shipping stable isotopes worldwide.
- AMIC has licensed the intellectual property rights for an advanced neutron production device.
- AMIC is developing a proprietary production method to manfacture Molybdenum 99 (Mo-99) - a method which the Company believes will be the fastest and least expensive with highest yeild to solve the current critical shortage of Mo-99.
- AMIC is devoping new breakthroughs in brachytherapy (implanted nuclear medicine agents for treatment of many solid tumor cancers) ultizing resorbable Yttrium-90 (Y-90) seeds.
- Comprised of top industry experts for isotope production and application, AMIC offers a highly experienced management team to move the company forward.
DISCLAIMER This newsletter is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Because we are compensated for these advertisements this email constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Investing in securities carries a high degree of risk that you may lose some or all of the investment. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the unsubscribe link at the bottom of this e-mail. Small Cap Voice SCV is an electronic publication, and is for informational purposes only. The stocks profiled by SCV are compiled from publicly available sources. Our sources include, but are not limited to, online research, company profiles, member suggestions, magazines, newspapers, analyst suggestions, contact with the company, press releases and other similar information sources. All profiles are based on information that is accessible by the public. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies tend to be new and have no proven track record. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. Small Cap Voice will receive $2,500 per month and 100,000 restricted shares subject to Rule 144 of the Securities Act of 1933 starting on 2-24-11 for 6 months of service. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website. http://smallcapvoice.com/blog/about-penny-stocks/ |
